A pivotal phase III trial of memantine extended release (ER) /donepezil HCl in patients with moderate to severe Alzheimer's disease on a stable dose of donepezil.

Trial Profile

A pivotal phase III trial of memantine extended release (ER) /donepezil HCl in patients with moderate to severe Alzheimer's disease on a stable dose of donepezil.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jan 2015

At a glance

  • Drugs Donepezil/memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ADS-DEM-DM303
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 18 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top